Group 1 - The core stock, Electric Science and Technology Blue Sky (stock code 688818), opened at 80.50 CNY, representing a 750.05% increase from its issue price of 9.47 CNY, making it the largest gain among new stocks this year [1] - Electric Science and Technology Blue Sky is part of the China Electronics Technology Group Corporation, focusing on advanced electric energy systems and core product solutions, with applications ranging from deep sea to deep space [3] - The company’s main business includes aerospace power, special power, and new energy applications, with a domestic market coverage of over 50% for its aerospace power products by 2024, supporting key national projects such as the Shenzhou series spacecraft and the Tiangong space station [3] Group 2 - Two other new stocks listed on the same day include N Linping, which opened at 63.11 CNY with a 66.61% increase, focusing on the development and production of corrugated paper and boxboard products [3] - The other stock, N Aide, opened at 25 CNY with a 225.95% increase, specializing in the research and production of orthopedic medical devices, including spinal and trauma-related products [3]

Group 1: Linping Development (603284) - Linping Development focuses on the research, production, and sales of corrugated paper and boxboard products, recognized as a high-tech enterprise with independent R&D capabilities [2] - The company is controlled by Li Jianshe, who holds 84.86% of the shares directly and an additional 3.54% indirectly, totaling 88.40% of the voting rights [2] - The total funds raised by Linping Development amount to 714.18 million yuan, with a net amount of 624.09 million yuan allocated for projects including the annual production of 900,000 tons of green intelligent manufacturing new materials [2] Group 2: Electric Science Blue Sky (688818) - Electric Science Blue Sky specializes in the R&D, production, sales, and services of electric energy products and systems, covering applications from deep sea to deep space [3] - The company is primarily controlled by China Electronics Technology Group Corporation, which holds 48.97% of the shares directly and additional indirect holdings, resulting in a total control of 84.50% of the voting rights [3] - The total funds raised by Electric Science Blue Sky are 1.64 billion yuan, with a net amount of 1.58 billion yuan designated for the industrialization of aerospace power systems [4] Group 3: Aide Technology (920180) - Aide Technology is engaged in the R&D, production, and sales of orthopedic medical devices, focusing on products such as spinal, trauma, and sports medicine consumables [5] - The company is controlled by Lu Qiang and Huang Meiyu, who together hold 79.07% of the shares before the issuance, with a reduction to 59.30% post-issuance [5] - The total funds raised by Aide Technology amount to 226.50 million yuan, with a net amount of 196.99 million yuan allocated for projects including the expansion of orthopedic consumables production and the establishment of a research center [5]

Group 1: New Stock Listings - Three new stocks are listed today: Linping Development on the Shanghai Stock Exchange, Dianke Lantian on the Sci-Tech Innovation Board, and Aide Technology on the Beijing Stock Exchange [1][2][5] Group 2: Linping Development - Linping Development is a leading paper manufacturing company in Anhui Province, focusing on the research, production, and sales of corrugated paper and boxboard products [1] - The company achieved revenues of 2.879 billion yuan, 2.800 billion yuan, and 2.485 billion yuan for the years 2022, 2023, and 2024 respectively, with net profits of 154 million yuan, 212 million yuan, and 153 million yuan [1] - For 2025, the company forecasts a revenue growth of 6.23% to 2.87 billion yuan and a net profit increase of 17.76% to 2.12 billion yuan [1] Group 3: Dianke Lantian - Dianke Lantian is a leader in aerospace power systems in China, with products including space solar battery arrays and lithium-ion battery packs, serving national and commercial aerospace sectors [1] - The company has become a major supplier for large satellite constellations, supporting over 700 spacecraft and covering significant national projects [1] - The aerospace power business accounted for 74% of the company's revenue, with a domestic market share exceeding 50% [1] Group 4: Aide Technology - Aide Technology specializes in the research, production, and sales of orthopedic medical devices, focusing on spinal, trauma, and sports medicine products [2][6] - The company reported revenues of 262.1 million yuan, 274.9 million yuan, and 301.7 million yuan for the years 2023, 2024, and 2025 respectively, with net profits of 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan [2] - The company forecasts a revenue growth of 0.35% to 3.85 million yuan for 2025, while net profit is expected to fluctuate between -3.18% to 6.81% [2]

Group 1: Company Overview - Yisiwei (Hangzhou) Technology Co., Ltd. focuses on the research, production, and sales of machine vision equipment for automotive manufacturing, providing solutions for various processes in vehicle and component manufacturing [2] - The company is controlled by Guo Yin, who directly holds 12.27% of the shares and indirectly controls a total of 56.13% of the company through various entities [3] Group 2: IPO Details - Yisiwei plans to raise approximately 1.214 billion yuan for projects including the industrialization base for machine vision products, a research and development center, and to supplement working capital [3] - The company is set to issue 25 million shares at a price of 55.95 yuan per share, with an expected total fundraising amount of 1.399 billion yuan, resulting in a net amount of approximately 1.282 billion yuan after deducting issuance costs [3]

New IPOs This Week - Two new stocks are scheduled for subscription this week: Yisiwei (688816) and Aide Technology (920180) [1][3] - Yisiwei is a leader in automotive manufacturing machine vision equipment and plays a significant role in the localization process of this field in China [1][5] - Aide Technology focuses on the research, production, and sales of orthopedic medical devices, primarily orthopedic consumables [6][7] Company Overview: Yisiwei - Established in 2017, Yisiwei has developed over ten products that are applied across six major manufacturing processes: stamping, welding, painting, assembly, battery, and die-casting [1][5] - The company has achieved a competitive advantage by offering a comprehensive range of products and significantly reducing the costs of machine vision equipment for the domestic automotive industry [5] - Yisiwei has established partnerships with over 80% of domestic passenger car manufacturers [1][5] Company Overview: Aide Technology - Aide Technology has been in the orthopedic medical device industry for over ten years, focusing on clinical needs and developing a comprehensive product matrix covering various orthopedic fields [6][7] - The company initially specialized in spinal minimally invasive intervention and has expanded its offerings to include products for trauma, sports medicine, and wound healing [7] - Aide Technology aims to become a leading provider of comprehensive orthopedic surgical solutions in China [6][7] Market Position and Financials - Yisiwei's revenue scale is below the average of comparable companies, which is projected to be 1.573 billion yuan for 2024, with an average gross margin of 49.11% [5] - Aide Technology's revenue and gross margin are also below the average of its comparable companies, which have an average revenue of 1.166 billion yuan and a gross margin of 64.61% [7]

Investment Rating - The investment rating for the company is "Buy" with an expected relative increase of over 15% in the next 6-12 months compared to the relevant market index [40]. Core Insights - The company, Aide Technology (920180.BJ), primarily engages in the research, production, and sales of orthopedic medical devices, focusing on spinal, trauma, and sports medicine products, as well as wound healing products [6][8]. - The company has a strong market position in the orthopedic field, particularly in the spinal segment, with a market share of 1.29% in 2023, ranking sixth among domestic companies in the spinal implant market [33]. - Revenue projections for 2023-2025 are 262 million, 275 million, and 302 million yuan respectively, with year-over-year growth rates of -8.22%, 4.87%, and 9.74% [8][3]. - The company has launched new products in the hip and knee joint categories, expanding its product line and aiming for steady revenue growth [34]. Summary by Sections Basic Financial Status - The company achieved revenues of 262.1 million yuan in 2023, with a net profit of 63.6 million yuan, reflecting a year-over-year decline of 31.85% [3][8]. - The revenue for 2024 is projected to be 274.9 million yuan, with a slight recovery in net profit to 67.1 million yuan, indicating a growth of 5.60% [3][8]. Industry Situation - The orthopedic medical device industry is experiencing growth, driven by an aging population and increasing healthcare spending, with the market size expected to grow from 193 billion yuan in 2016 to 246 billion yuan by 2024 [16][17]. - The spinal implant market specifically is projected to recover in 2024, with a market size of 72 billion yuan, following a decline due to national procurement policies [18]. Company Highlights - Aide Technology has developed a comprehensive product matrix covering all areas of orthopedics, with 132 product registrations and a focus on the lower-tier medical market [33][34]. - The company has established a nationwide sales network, collaborating with over 3,000 hospitals across 31 provinces and municipalities [33]. Fundraising Project Investment - The company plans to invest in three main projects through its IPO: an orthopedic consumables expansion project, a research and development center, and a marketing network enhancement project [35][36]. Comparison with Peers - Compared to peer companies like Weigao Orthopedics and Dabo Medical, Aide Technology's revenue and gross margin are below the average, with a projected revenue of 2.75 billion yuan for 2024 [37][38].

Group 1: Company Overview - Yisiwei's IPO price is set at 7.67 CNY per share, focusing on machine vision equipment for the automotive manufacturing sector, providing solutions across various manufacturing processes [1] - The company is projected to achieve a market share of 13.7% in China's automotive manufacturing machine vision market and 22.5% in the overall automotive manufacturing sector by 2024, leading the industry [1] - Yisiwei has developed over ten products, covering six major manufacturing processes, establishing a comprehensive product range and application advantage, serving most domestic automotive manufacturers [1] Group 2: Business Growth and Financial Performance - From 2022 to 2024, Yisiwei's revenue is expected to grow from 22.3 million CNY to 39.2 million CNY, with a compound annual growth rate (CAGR) of 32.59%, while net profit is projected to increase from 5.39 million CNY to 84.43 million CNY, with a CAGR of 295.66% [2] - Aide Technology's IPO price is set at 55.95 CNY per share, focusing on orthopedic medical devices, including spinal, trauma, and sports medicine products [2] - The total fundraising amount for Aide Technology is 197.02 million CNY, aimed at expanding orthopedic consumables production, building a research center, and developing a marketing network [2] Group 3: Market Trends - The market size for orthopedic implant medical devices in China is expected to grow from 19.3 billion CNY in 2016 to 24.6 billion CNY by 2024, with a CAGR of 3.08%, despite a recent market contraction due to procurement policies [2] - Specific segments, such as the sports medicine market, continue to show growth despite overall market challenges [2]

Group 1: Company Overview - Yisiwei is a leading domestic company in automotive manufacturing machine vision equipment, holding the largest market share in China [2] - Aide Technology specializes in orthopedic consumables, focusing on the research, production, and sales of medical devices [3] Group 2: Financial Performance - Yisiwei's projected revenues for 2022 to 2024 are 223 million, 355 million, and 392 million yuan, with net profits of 6 million, 61 million, and 86 million yuan respectively [2] - Aide Technology's projected revenues from 2022 to 2025 are 286 million, 262 million, 275 million, and 302 million yuan, with net profits of 93 million, 64 million, 67 million, and 78 million yuan respectively [3] Group 3: Market Position and Growth Potential - Yisiwei's products are widely used by mainstream joint ventures, domestic new forces, and well-known automotive parts companies, indicating strong market penetration [2] - Aide Technology ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, showcasing its competitive position [3] Group 4: Upcoming IPO Details - Yisiwei's IPO price is set at 55.95 yuan per share with a price-to-earnings ratio of 90.39, while Aide Technology's IPO price is 7.67 yuan per share with a price-to-earnings ratio of 14.98 [1][3]

Group 1: New Stock Offerings - Two new stocks are available for subscription on February 2, including Yisiwei on the Sci-Tech Innovation Board and Aide Technology on the Beijing Stock Exchange [2] - Aide Technology's total issuance, online issuance, and subscription limit rank first among new stocks on the Beijing Stock Exchange since 2026, with a subscription limit of 1.3288 million shares [2][3] - The total issuance of Aide Technology is 29.53 million shares, with 26.58 million shares available for online subscription [4] Group 2: Aide Technology Overview - Aide Technology is a leading company in the domestic medical device sector, focusing on orthopedic consumables, including spinal, trauma, and sports medicine products [4][6] - The company ranks third in the domestic market for spinal vertebral body augmentation systems and sixth for spinal implant medical devices [6] - Aide Technology's revenue for 2022 to 2025 is projected to be 286 million, 262 million, 275 million, and 149 million yuan, respectively, with net profits of approximately 93.28 million, 63.57 million, 67.13 million, and 38.15 million yuan [8][9] Group 3: Yisiwei Overview - Yisiwei is a leading company in the domestic machine vision sector, focusing on the development, production, and sales of machine vision equipment for automotive manufacturing [10][11] - The total issuance of Yisiwei is 25 million shares, with 6 million shares available for online subscription and a subscription limit of 600 shares [11] - Yisiwei's revenue for 2022 to 2025 is projected to be 223 million, 355 million, 392 million, and 125 million yuan, respectively, with net profits of approximately 6.12 million, 61.06 million, 85.64 million, and a loss of 509,910 yuan [13][14]

Investment Rating - The report suggests a focus on the company, with a recommendation to pay attention to its competitive position in the orthopedic surgical solutions market [4][42]. Core Insights - The company, Aide Technology, specializes in orthopedic consumables and has a projected net profit of 77.75 million yuan for 2025, reflecting a year-on-year increase of 15.82% [4][39]. - The company plans to use the funds raised from its IPO for expanding production capacity, building a research center, and developing a marketing network, which is expected to enhance sales scale and market share [12][14]. - The orthopedic medical device market in China is projected to reach 24.6 billion yuan by 2024, with significant growth in various segments such as spinal implants and trauma devices [42][50]. Company Overview - Aide Technology was established in 2006 and focuses on the research, production, and sales of orthopedic medical devices, including spinal, trauma, and sports medicine products [14][39]. - The company holds 110 patents and has several core products certified by the EU CE authority [14][39]. - The sales model primarily relies on distributors, with the top five customers accounting for 31.87% of total sales in the first half of 2025 [35][36]. Financial Performance - Revenue is projected to grow from 262 million yuan in 2023 to 302 million yuan in 2025, with a compound annual growth rate (CAGR) of 2% from 2022 to 2025 [39]. - The gross margin is expected to decline slightly from 62.45% in 2022 to 58.90% in 2025, while the net profit margin is projected to decrease from 32.70% to 25.85% over the same period [39][41]. Industry Insights - The orthopedic medical device industry is rapidly growing, with the market for orthopedic implants expected to reach 24.6 billion yuan by 2024 [42][50]. - The spinal implant market specifically is projected to grow to 7.2 billion yuan in 2024, despite a temporary decline due to national procurement policies [46][48]. - The trauma implant market is also expected to recover, reaching 3.9 billion yuan in 2024, following a downturn in previous years [52].